Tata Elxsi Wins Deal From China IT Ministry, Shares Jump
Tata Elxsi shares rose 2.7 per cent to hit an intraday high of Rs 1,424.95 on Tuesday, after the company announced winning of a contract from China's IT ministry in partnership with Spirent.
The Tata group company in a regulatory filing announced the adoption of the V2X test system by CAICT (China Academy of Telecommunication Research of MIIT), a scientific research institute directly under the Ministry of Industry and Information Technology of China.
This next generation test system is developed in partnership with Spirent, Tata Elxsi said.
The system "provides a flexible, scalable and comprehensive test environment for testing and performance benchmarking of V2X applications, in various stages of the development cycle, right from early research up to pre-production", the Bengaluru-based design company said.
A part of the $100-billion Tata group, Tata Elxsi addresses the communications, consumer products, defence, healthcare, media & entertainment, semiconductor and transportation sectors.
"V2X technology is gaining tremendous interest among global OEMs & Tier-1 companies for delivering safer driving experience. The V2X Test System, developed by us, enables multi-standards compliance testing using a single solution," said Nitin Pai, senior vice president-marketing at Tata Elxsi.
"With China being the largest automotive market in the world, this latest win with CAICT in China is significant for us, and automotive companies targeting this market," Mr Pai added.
At 10:21 a.m., shares in Tata ELXSI were trading 1.97 per cent higher at Rs 1,415.20 apiece on the National Stock Exchange, outperforming the broader Nifty index which was up 0.42 per cent.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.